Can a smaller dose of a drug ease the pain of pregnancy loss?
NCT ID NCT06909123
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of cabergoline can safely prevent lactation and breast discomfort after second-trimester abortion or pregnancy loss. The standard dose works but can be costly and cause side effects. Researchers will enroll 36 people to compare the reduced dose with the usual dose, using blood tests and symptom surveys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabergoline (Dostinex)
- What this could lead to
- If successful, this could provide a cheaper, more tolerable option to prevent breast pain and milk production after second-trimester pregnancy loss or abortion.
- What could go wrong
- This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The reduced dose might be less effective at stopping lactation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LACTATION SUPPRESSED are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.